OR WAIT null SECS
August 01, 2018
The companies will work together to develop novel gamma delta T-cell receptor therapies in various cancers.
CMOs have been active over the past year in expanding their biologics production and capabilities.
July 27, 2018
Novartis is set to partner with MorphoSys and Galapagos in a deal worth up to $1.1 billion to develop and commercialize their joint investigational, fully human, IgG1 monoclonal antibody (mAb) directed against the target IL-17C.
Waters’ acquisition of Prosolia’s DESI technology boosts its mass spectrometry imaging portfolio.
July 18, 2018
CELLforCURE will produce cancer CAR-T treatments for Novartis at a manufacturing facility in Les Ulis (Essonne), France.
July 16, 2018
Otsuka Pharmaceutical will acquire Visterra, a clinical-stage biotechnology company focused on developing antibody-based therapies, for approximately $430 million.
July 11, 2018
The company has received clearance from the United States Federal Trade Commission for the proposed acquisition of Shire, a deal valued at $62 billion.
July 03, 2018
Biogen will pay Samsung BioLogics approximately $700 million to increase its stake in Samsung Bioepis to approximately 49.9%.
The pharma major intends to spinoff Alcon as a stand-alone eye-care devices company.
June 29, 2018
Sanofi will sell Zentiva, its European generics business, to private equity investor Advent International.